Clarinex RediTabs
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's Clarinex (desloratadine) RediTabs formulation has been approved for the treatment of allergic rhinitis and chronic idiopathic urticaria, FDA announces July 15. The Claritin (loratadine) follow-on is currently prescription-only. The RediTabs formulation disintegrates orally for once-daily 24-hour relief. Clarinex RediTabs will be available in pharmacies September 2005 in a 2.5 mg and 5 mg dose. The tablet also comes in a new "tutti frutti" flavor...
You may also be interested in...
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.